Clinical Trial Update: Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

Phase IIb/III study of BL-1020 for schizophrenia was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Bl-1020

Snippet

Sponsor: BioLineRx, Ltd. | Conditions: Schizophrenia, Cognitive Effect on Schizophrenic Patients | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2014-09-18